[go: up one dir, main page]

GB201621398D0 - Treatment of emt-associated disease - Google Patents

Treatment of emt-associated disease

Info

Publication number
GB201621398D0
GB201621398D0 GBGB1621398.5A GB201621398A GB201621398D0 GB 201621398 D0 GB201621398 D0 GB 201621398D0 GB 201621398 A GB201621398 A GB 201621398A GB 201621398 D0 GB201621398 D0 GB 201621398D0
Authority
GB
United Kingdom
Prior art keywords
emt
treatment
associated disease
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1621398.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Priority to GBGB1621398.5A priority Critical patent/GB201621398D0/en
Publication of GB201621398D0 publication Critical patent/GB201621398D0/en
Priority to PCT/GB2017/053763 priority patent/WO2018109491A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1621398.5A 2016-12-15 2016-12-15 Treatment of emt-associated disease Ceased GB201621398D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1621398.5A GB201621398D0 (en) 2016-12-15 2016-12-15 Treatment of emt-associated disease
PCT/GB2017/053763 WO2018109491A1 (en) 2016-12-15 2017-12-15 Treatment of emt-associated disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1621398.5A GB201621398D0 (en) 2016-12-15 2016-12-15 Treatment of emt-associated disease

Publications (1)

Publication Number Publication Date
GB201621398D0 true GB201621398D0 (en) 2017-02-01

Family

ID=58284347

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1621398.5A Ceased GB201621398D0 (en) 2016-12-15 2016-12-15 Treatment of emt-associated disease

Country Status (2)

Country Link
GB (1) GB201621398D0 (en)
WO (1) WO2018109491A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127805A1 (en) * 2016-03-15 2019-05-02 Almac Diagnostics Limited Gene signatures for cancer detection and treatment

Also Published As

Publication number Publication date
WO2018109491A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL256175A (en) Use of exosomes for the treatment of disease
PT3212233T (en) Combination therapy for treatment of disease
IL253945A0 (en) Kdm1a inhibitors for the treatment of disease
GB201618424D0 (en) Treatment of antibody mediated disease
GB201412578D0 (en) Treatment of neurological diseases
IL263835A (en) Exosome-guided treatment of cancer
ZA201705847B (en) Treatment of pain
PL3484475T3 (en) 1-methylnicotinamide for the treatment of cardiovascular disease
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL253847A0 (en) Methods of treating diseases
GB201603546D0 (en) Treatment of urine
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL259381B (en) Miravegron for the treatment of retinal diseases
PT3302499T (en) Treatment of mitochondrial diseases
GB201515244D0 (en) Treatment of inflammatory disease or condition
GB201410407D0 (en) Treatment of chagas disease
IL272422A (en) Methods for the treatment of leptomeningeal disease
GB201412010D0 (en) Treatment of hypertransaminasemia
IL263837A (en) Treatment of ocular disease
GB201622116D0 (en) Treatment of liver disease
GB201604359D0 (en) Treatment of tissue disorders
GB201512139D0 (en) Methods of treatment
GB201621398D0 (en) Treatment of emt-associated disease
GB201504413D0 (en) Treatment of disease

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: ALMAC DISCOVERY LIMITED

Free format text: FORMER OWNER: ALMAC DIAGNOSTICS LIMITED

AT Applications terminated before publication under section 16(1)